News | Prostate Cancer | September 14, 2017

Double Targeting Ligands to Identify and Treat Prostate Cancer

Researchers demonstrate a theranostic one-two punch that precisely identifies cancer cells for destruction with targeted therapy, while sparing healthy cells

Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

September 14, 2017 — Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while protecting healthy tissue and reducing side effects. The new approach utilizes a single molecule designed to bind two proteins with differing affinities in an effort to optimize specific tumor localization — prostate-specific membrane antigen (PSMA) and human serum albumin — thereby enhancing tumor localization for targeted alpha radionuclide therapy. The study is presented in the featured basic article of the September issue of The Journal of Nuclear Medicine.

PSMA-targeted radiotherapy of prostate cancer is a promising approach to the treatment of disease that has spread. A small number of ligands have been evaluated in patients, and while early tumor response is encouraging, the relapse rate is high and these compounds can cause adverse side effects.

“We see now the pitfalls of PSMA targeting and have attempted to circumvent some of these by improved molecular design,” explained John W. Babich, Ph.D., professor of radiopharmaceutical sciences in radiology at Weill Cornell Medicine, New York. “We believe that our double targeting ligands are the first PSMA ligands designed to make use of the blood pool as a ‘safe zone’ reservoir to protect sensitive organs and tissues from off-target effects of alpha irradiation and, simultaneously, to reduce kidney localization while maintaining excellent tumor targeting.”

The goal is to develop a way of optimizing therapy by increasing the dose delivered to the tumor while simultaneously reducing damage to healthy tissue. To that end, the research team developed the double targeting ligand RPS-027, which binds to both PSMA and albumin. It was tested in mouse models of human prostate cancer, and the results, assessed via positron emission tomography/computed tomography (PET/CT), show high tumor uptake, with reduced kidney uptake; very favorable tissue distribution; and a promising therapeutic profile. In comparison to existing ligands proposed for targeted therapy of prostate cancer, RPS-027 has tumor-to-tissue ratios that predict a significant reduction in side effects during therapy. The researchers propose dual targeting ligands such as RPS-027 as next-generation radiopharmaceuticals for targeted alpha therapy using Astatine-211 (211At).

“Designing ligands that allow modulation of normal tissue localization can have a positive impact on the therapeutic index of alpha therapy and lead to widespread clinical utility,” Babich pointed out. “If our strategy can be applied successfully to other therapeutic targeting agents, we could expect an expansion in the use of targeted alpha therapy in the not-too-distant future.”

The use of theranostics (combined diagnostic targeting and therapy) for precision medicine is already revolutionizing the care of patients with thyroid cancer and neuroendocrine tumors. Studies such as this one show real promise for their use against prostate cancer and other diseases. They also highlight the key role of nuclear medicine in developing new therapies that improve patients’ lives.

For more information: www.jnm.snmjournals.org

Related Content

New ASNC SPECT Imaging Guideline Addresses Advances in Myocardial Perfusion Imaging
News | SPECT Imaging | June 21, 2018
The American Society of Nuclear Cardiology (ASNC) has published an update to its 2010 guidelines for single photon...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
Technology | Focused Ultrasound Therapy | June 19, 2018
EDAP TMS SA has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Focal One device for...
New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Elekta Unity High-Field MR-Linac Receives CE Mark
News | Image Guided Radiation Therapy (IGRT) | June 18, 2018
Elekta announced that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received CE mark,...
Hitachi Medical Systems Europe Named Imaging Supplier for London Prostate Cancer Program
News | Prostate Cancer | June 14, 2018
Hitachi Medical Systems Europe has been awarded the contract to supply six ultrasound systems as part of the RAPID...
Washington University in St. Louis Begins Clinical Treatments With ViewRay MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 14, 2018
June 14, 2018 — The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in S
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Accuray TomoTherapy System Beneficial in Two Total Body Irradiation Studies
News | Radiation Therapy | June 13, 2018
Recently published data from two new studies demonstrate the benefits of Accuray’s TomoTherapy System in the delivery...
IsoRay Funding Brain Cancer Treatment Research With Ochsner Clinic Foundation
News | Brachytherapy Systems | June 12, 2018
IsoRay Inc. announced the initiation of research funding for brain cancer treatment to Ochsner Clinic Foundation, a not...
Overlay Init